X0202 SCHEDULE 13G/A 0001442891 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 06/30/2026 0001636651 Ovid Therapeutics Inc. 690469101 441 Ninth Avenue, 14th floor New York NY 10001 Rule 13d-1(b) Eventide Asset Management, LLC DE 11812241.00 0.00 11812241.00 0.00 11812241.00 N 6.3 IA Finny Kuruvilla, M.D., Ph. D. X1 0.00 11812241.00 0.00 11812241.00 11812241.00 N 6.3 HC IN Robin C. John X1 0.00 11812241.00 0.00 11812241.00 11812241.00 N 6.3 HC IN Ovid Therapeutics Inc. 441 Ninth Avenue, 14th floor, New York, NY 10001 (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John") Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110 Eventide: Delaware Kuruvilla: United States John: United States N IA HC (i) Eventide: 11,812,241 (ii) Kuruvilla: 11,812,241 (iii) John: 11,812,241 (i) Eventide: 6.3% (ii) Kuruvilla: 6.3% (iii) John: 6.3% (1) Eventide: 11,812,241 (2) Kuruvilla: 0 (3) John: 0 (1) Eventide: 0 (2) Kuruvilla: 11,812,241 (3) John: 11,812,241 (1) Eventide: 11,812,241 (2) Kuruvilla: 0 (3) John: 0 (1) Eventide: 0 (2) Kuruvilla: 11,812,241 (3) John: 11,812,241 Y N As of June 30, 2026, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 11,812,241 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Healthcare & Life Sciences Fund which is a registered investment company. As of June 30, 2026, the Eventide Healthcare & Life Sciences Fund held 11,812,241 shares of the Issuer's Common Stock, representing 6.3% of the Issuer's outstanding Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities. EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them; NOW, THEREFORE, the parties hereto agree as follows: Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them. Eventide Asset Management, LLC Date: August 14, 2026 By: /s/ Peter J. Luiso Name: Peter J. Luiso Title: General Counsel Finny Kuruvilla, M.D., Ph. D. Date: August 14, 2026 By: /s/ Finny Kuruvilla, M.D., Ph. D. Name: Finny Kuruvilla, M.D., Ph. D. Robin C. John Date: August 14, 2026 By: /s/ Robin C. John Name: Robin C. John Eventide Asset Management, LLC /s/ Peter J. Luiso 08/14/2026 Finny Kuruvilla, M.D., Ph. D. /s/ Finny Kuruvilla, M.D., Ph. D. 08/14/2026 Robin C. John /s/ Robin C. John 08/14/2026